PRAZIQUANTEL

Praziquantel increases calcium permeability in parasitic worms, causing rapid spastic paralysis and tegument damage, leading to elimination. It is used for schistosomiasis and tapeworm infections. Benefits include high cure rates with short courses. Side effects include abdominal pain, dizziness, headache, fatigue, and allergic or inflammatory reactions related to parasite death. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 1464c945a3c5 Category: Tag:

Product Description


Mechanism of Action

PRAZIQUANTEL exhibits a complex, multipathway biochemical activity profile influencing enzymatic cascades, receptormediated signalling networks, mitochondrial respiration, oxidativestress balance, intracellular ion regulation, membranepotential stability and transcriptionfactor activation. Its structural framework suggests potential interactions with catalytic residues, allosteric regulatory pockets, membraneembedded receptor complexes and intracellular signalling scaffolds. These interactions may modulate phosphorylation patterns, secondmessenger systems (Ca²⁺, IP, DAG, cAMP), ATP turnover, ROS equilibrium, cytoskeletal organisation and organelle stressresponse thresholds.

Depending on dosing, PRAZIQUANTEL can influence metabolic flux routing, alter chromatin accessibility, modify vesicular transport, reshape mitochondrial output and regulate transcriptional clusters associated with cellular survival, apoptosis, autophagy, inflammatory signalling and metabolic adaptation. This multiaxis behaviour supports its wide applicability in advanced biochemical and pharmacodynamic research systems.

Benefits and Advantages

The compound is widely utilised for:

  • Receptorligand interaction analysis and affinity modelling
  • Enzymekinetic profiling and catalyticpathway reconstruction
  • Mitochondrialbioenergetics assays and oxidativestress evaluation
  • Multiomics integration (transcriptomics, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal and membranedynamics studies
  • Apoptosis, necroptosis, autophagy and ferroptosis pathway characterisation
  • SAR (structureactivity relationship) development and molecular screening
  • Pharmacodynamic modelling and mechanistic doseresponse simulations

Side Effects and Risks

Potential laboratoryobserved risks include:

  • Excessive ROS production and oxidative imbalance
  • Mitochondrial hyperactivation or suppression of electrontransport complexes
  • Ionchannel dysregulation (Na⁺, K⁺, Ca²⁺)
  • Unintended receptor crosstalk or inhibition
  • Cytoskeletal destabilisation and membrane-integrity compromise
  • Dosedependent cytotoxicity or activation of apoptotic/autophagic pathways
  • Transcriptional or epigenetic instability
  • Upregulation of inflammatory cascades (NF-κB, JNK, p38 MAPK)

Use exclusively within controlled laboratory conditions and according to strict biosafety standards.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C19H24N2O2

Molecular Weight

312.4 g/mol

CAS Number

55268-74-1

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

praziquantel; 55268-74-1; Biltricide; Droncit; Embay 8440

IUPAC/Chemical Name

2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one

InChl Key

FSVJFNAIGNNGKK-UHFFFAOYSA-N

InChl Code

InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

References

https://pubchem.ncbi.nlm.nih.gov/compound/4891;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download